Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis

Journal of Clinical Oncology

Volumn 25, Issue 4, 2007, Pages 349-355

  Shariat, Shahrokh F ^a   Roehrborn, Claus G ^a   McConnell, John D ^a   Park, Sangtae ^a   Alam, Nina ^a   Wheeler, Thomas M ^a   Slawin, Kevin M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; UROKINASE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; PLASMINOGEN ACTIVATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; TUMOR VOLUME; UNIVARIATE ANALYSIS; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY;

AGED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 33846978442     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.6853     Document Type: Article

References (27)

1. Andreasen PA, Kjoller L, Christensen L, et al: The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 72:1-22, 1997
2. Chapman HA: Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 9:714-724, 1997
3. Rabbani SA, Mazar AP: The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 10:393-415, 2001
4. Xing RH, Rabbani SA: Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer 67:423-429, 1996
5. Busso N, Masur SK, Lazega D, et al: Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells. J Cell Biol 126:259-270, 1994
6. Duffy MJ: Urokinase-type plasminogen activator: A potent marker of metastatic potential in human cancers. Biochem Soc Trans 30:207-210, 2002
7. Janicke F, Prechtl A, Thomssen C, et al: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93:913-920, 2001
8. Look MP: Pooled analysis of uPA and PAI-1 for prognosis in primary breast cancer patients: EORTC Receptor and Biomarker Study Group. Int J Biol Markers 15:70-72, 2000
9. Sier CF, Stephens R, Bizik J, et al: The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58:1843-1849, 1998
10. Fernebro E, Madsen RR, Ferno M, et al: Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 37:486-491, 2001
11. Stephens RW, Nielsen HJ, Christensen IJ, et al: Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst 91:869-874, 1999
12. Shariat SF, Monoski MA, Andrews B, et al: Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology 61:1053-1058, 2003
13. Gaylis FD, Keer HN, Wilson MJ, et al: Plasminogen activators in human prostate cancer cell lines and tumors: Correlation with the aggressive phenotype. J Urol 142:193-198, 1989
14. Keer HN, Gaylis FD, Kozlowski JM, et al: Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: Increased PA activity correlates with biologically aggressive behavior. Prostate 18:201-214, 1991
15. Hoosein NM, Boyd DD, Hollas WJ, et al: Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 3:255-264, 1991
16. Achbarou A, Kaiser S, Tremblay G, et al: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54:2372-2377, 1994
17. Kirchheimer JC, Pfluger H, Ritschl P, et al: Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 5:344-355, 1985
18. Kirchheimer J, Koller A, Binder BR: Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue. Biochim Biophys Acta 797:256-265, 1984
19. Camiolo SM, Markus G, Englander LS, et al: Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues. Cancer Res 44:311-318, 1984
20. Van Veldhuizen PJ, Sadasivan R, Cherian R, et al: Urokinase-type plasminogen activator expression in human prostate carcinomas. Am J Med Sci 312:8-11, 1996
21. Hienert G, Kirchheimer JC, Christ G, et al: Plasma urokinase-type plasminogen activator correlates to bone scintigraphy in prostatic carcinoma. Eur Urol 15:256-258, 1988
22. Hienert G, Kirchheimer JC, Pfluger H, et al: Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 140:1466-1469, 1988
23. Miyake H, Hara I, Yamanaka K, et al: Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39:123-129, 1999
24. Henson DE, Hutter RV, Farrow G: Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland: A publication of the Cancer Committee, College of American Pathologists, Task Force on the Examination of Specimens Removed From Patients With Prostate Cancer. Arch Pathol Lab Med 118:779-783, 1994
25. Schmid HP, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer: The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71:2031-2040, 1993
26. Holst-Hansen C, Hamers MJ, Johannessen BE, et al: Soluble urokinase receptor released from human carcinoma cells: A plasma parameter for xenograft tumour studies. Br J Cancer 81:203-211, 1999
27. Riisbro R, Christensen IJ, Piironen T, et al: Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 8:1132-1141, 2002